Area of research
Radiology, Nuclear Medicine and Imaging · Pulmonary and Respiratory Medicine
Research interest
Research interests include Prostate Cancer Treatment and Research, Medical Imaging Techniques and Applications, Radiopharmaceutical Chemistry and Applications, and Prostate Cancer Diagnosis and Treatment.
Therapy strategies to defeat prostate cancer heterogeneity
MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.
Clinical Trials in Cancer Theranostics with Potential Near-Term Impact on Clinical Practice.
Diagnostic Accuracy of [<sup>18</sup>F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis
Telehealth and Telemedicine: Regulatory and Medicolegal Landscape.
Tracking Docetaxel-Induced Cellular Proliferation Changes in Prostate Tumor-Bearing Mice with <sup>18</sup>F-FMAU PET.
Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer.
Management Impact of Metachronous Oligometastatic Disease Identified on <sup>18</sup>F-Fluciclovine (Axumin™) PET/CT in Biochemically Recurrent Prostate Cancer.
Exploratory Evaluation of 18F-FMAU PET in Tracking Response to Docetaxel Treatment in Prostate Tumor-Bearing Mice
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
Low-count whole-body PET with deep learning in a multicenter and externally validated study
Low-count whole-body PET with deep learning in a multicenter and externally validated study.
Management Impact of <sup>68</sup>Ga-DOTATATE PET/CT in Neuroendocrine Tumors.
Targeted α-therapy in non-prostate malignancies.
Competitive Advantage of PSMA Theranostics in Prostate Cancer.
Author Correction: Low-count whole-body PET with deep learning in a multicenter and externally validated study
Author Correction: Low-count whole-body PET with deep learning in a multicenter and externally validated study.
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with <sup>18</sup>F-NaF PET/CT.
Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.
Preclinical evaluation of a <sup>64</sup>Cu-labeled disintegrin for PET imaging of prostate cancer.
Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies
Future cancer research priorities in the USA: a Lancet Oncology Commission
The SNMMI Practice Guideline for Therapy of Thyroid Disease with <sup>131</sup>I 3.0
Preservation of retinotopic map in retinal degeneration